Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling

Kevin Fiscella, Peter Franks

Research output: Contribution to journalArticle

178 Citations (Scopus)

Abstract

Objective.-To determine the incremental cost-effectiveness of the transdermal nicotine patch. Design.-Decision analytic model that evaluated the incremental cost-effectiveness of the addition of the nicotine patch to smoking cessation counseling. Costs were based on physician time and the retail cost of the nicotine patch, and benefits were based on quality- adjusted life years (QALYs) saved. Patients.-Male and female smokers aged 25 to 69 years receiving primary care. Intervention.-Addition of the nicotine patch to physician-based smoking cessation counseling. Main Outcome Measure.- Costs (1995 dollars) per QALYs saved discounted by 3% annually. Results.-The use of the patch produced 1 additional lifetime quitter at a cost of $7332. The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10 943 per QALY for men and $4955 to $6983 per QALY for women. A clinical strategy involving limiting prescription renewals to patients successfully abstaining for the first 2 weeks improved the cost-effectiveness of the patch by 25%. Conclusions.-The findings provide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cessation counseling and for health insurance coverage of nicotine patch therapy.

Original languageEnglish (US)
Pages (from-to)1247-1251
Number of pages5
JournalJournal of the American Medical Association
Volume275
Issue number16
DOIs
StatePublished - Apr 24 1996
Externally publishedYes

Fingerprint

Tobacco Use Cessation Products
Smoking Cessation
Cost-Benefit Analysis
Counseling
Quality-Adjusted Life Years
Physicians
Costs and Cost Analysis
Insurance Coverage
Health Insurance
Prescriptions
Primary Health Care
Age Groups
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. / Fiscella, Kevin; Franks, Peter.

In: Journal of the American Medical Association, Vol. 275, No. 16, 24.04.1996, p. 1247-1251.

Research output: Contribution to journalArticle

@article{c68f442216b749548475a80df9758098,
title = "Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling",
abstract = "Objective.-To determine the incremental cost-effectiveness of the transdermal nicotine patch. Design.-Decision analytic model that evaluated the incremental cost-effectiveness of the addition of the nicotine patch to smoking cessation counseling. Costs were based on physician time and the retail cost of the nicotine patch, and benefits were based on quality- adjusted life years (QALYs) saved. Patients.-Male and female smokers aged 25 to 69 years receiving primary care. Intervention.-Addition of the nicotine patch to physician-based smoking cessation counseling. Main Outcome Measure.- Costs (1995 dollars) per QALYs saved discounted by 3{\%} annually. Results.-The use of the patch produced 1 additional lifetime quitter at a cost of $7332. The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10 943 per QALY for men and $4955 to $6983 per QALY for women. A clinical strategy involving limiting prescription renewals to patients successfully abstaining for the first 2 weeks improved the cost-effectiveness of the patch by 25{\%}. Conclusions.-The findings provide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cessation counseling and for health insurance coverage of nicotine patch therapy.",
author = "Kevin Fiscella and Peter Franks",
year = "1996",
month = "4",
day = "24",
doi = "10.1001/jama.275.16.1247",
language = "English (US)",
volume = "275",
pages = "1247--1251",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "16",

}

TY - JOUR

T1 - Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling

AU - Fiscella, Kevin

AU - Franks, Peter

PY - 1996/4/24

Y1 - 1996/4/24

N2 - Objective.-To determine the incremental cost-effectiveness of the transdermal nicotine patch. Design.-Decision analytic model that evaluated the incremental cost-effectiveness of the addition of the nicotine patch to smoking cessation counseling. Costs were based on physician time and the retail cost of the nicotine patch, and benefits were based on quality- adjusted life years (QALYs) saved. Patients.-Male and female smokers aged 25 to 69 years receiving primary care. Intervention.-Addition of the nicotine patch to physician-based smoking cessation counseling. Main Outcome Measure.- Costs (1995 dollars) per QALYs saved discounted by 3% annually. Results.-The use of the patch produced 1 additional lifetime quitter at a cost of $7332. The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10 943 per QALY for men and $4955 to $6983 per QALY for women. A clinical strategy involving limiting prescription renewals to patients successfully abstaining for the first 2 weeks improved the cost-effectiveness of the patch by 25%. Conclusions.-The findings provide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cessation counseling and for health insurance coverage of nicotine patch therapy.

AB - Objective.-To determine the incremental cost-effectiveness of the transdermal nicotine patch. Design.-Decision analytic model that evaluated the incremental cost-effectiveness of the addition of the nicotine patch to smoking cessation counseling. Costs were based on physician time and the retail cost of the nicotine patch, and benefits were based on quality- adjusted life years (QALYs) saved. Patients.-Male and female smokers aged 25 to 69 years receiving primary care. Intervention.-Addition of the nicotine patch to physician-based smoking cessation counseling. Main Outcome Measure.- Costs (1995 dollars) per QALYs saved discounted by 3% annually. Results.-The use of the patch produced 1 additional lifetime quitter at a cost of $7332. The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10 943 per QALY for men and $4955 to $6983 per QALY for women. A clinical strategy involving limiting prescription renewals to patients successfully abstaining for the first 2 weeks improved the cost-effectiveness of the patch by 25%. Conclusions.-The findings provide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cessation counseling and for health insurance coverage of nicotine patch therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029986831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029986831&partnerID=8YFLogxK

U2 - 10.1001/jama.275.16.1247

DO - 10.1001/jama.275.16.1247

M3 - Article

C2 - 8601956

AN - SCOPUS:0029986831

VL - 275

SP - 1247

EP - 1251

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 16

ER -